UCB is a global biopharmaceutical company focused on severe diseases that have significant unmet needs. By putting patients at the heart of everything we do, we enable people to live their best lives, delivering impactful solutions patients value.

At UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we live. It is our culture of care, embodied by our patient value strategy. That’s because how we do business – from discovery to development to delivery – has been transformed and redesigned around the patient and their individual experience. Patients are at the heart of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, more impactful solutions are on the horizon.

UCB is committed to communicating science simply, bridging provider and patient connectivity, and engaging authentically with the dermatology community. In our 90-plus-year history, we have developed breakthrough medicines for neurological and immunological conditions.

Let’s talk about you

We are committed to the dermatology community and strive to partner with and support you in meaningful ways. We look forward to getting to know you, learn from you, and listen to your needs and those of your patients and colleagues to truly make an impact.

A strong foundation

Learn more about the scientific breakthroughs, treatment advances, and partnerships that demonstrate and affirm UCB’s continued ambition to transform the lives of people living with severe diseases.

Briviact^®, Cimzia^®, Keppra XR^®, Keppra^®, Nayzilam^® and Neupro^® are registered trademarks of the UCB Group of Companies.  Vimpat^® is a registered trademark used under license from Harris FRC Corporation.

US-P-DA-PSO-2100024